"FDA Approval Includes Companion Diagnostic Claims for Rubraca® (rucaparib), the First PARP Inhibitor Approved in a Prostate Cancer Setting, and Three Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer
"FoundationOne Liquid CDx Analyzes More Than 300 Genes and Genomic Signatures to Help Inform Treatment Decisions for all Solid Tumor Cancers
"CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne®Liquid CDx, the Company’s comprehensive pan-tumor liquid biopsy test. FoundationOne Liquid CDx will be commercially available on Friday, August 28 and is covered across all solid tumors for eligible Medicare and Medicare Advantage beneficiaries in accordance with the Centers for Medicare and Medicaid Services National Coverage Decision Memo criteria."
click to read the full text: foundationmedicine.com/pres...
-Patrick